Université de Lorraine, CHRU Nancy and APEMAC
Vandœuvre-lès-Nancy, Lorraine, 54511, France
Completed
NCT Number: NCT05458752
Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients
Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection
- Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia
- Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)
Exclusion criteria
- No microbiological confirmation by respiratory specimen analyses
- Proved HIV infection
- Patient denied to particpate
Treatment and study plan
Primary outcomes
-
Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients
Time frame: Between the first january 2004 and the 31th december 2021
Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...)
Secondary outcomes
-
To describe the age of giv free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
age in years
-
To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
BMI in kg/m2 (quanti
-
To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Charlson comorbidity index as a quantitative variable
-
To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Comorbidities as categorial variables
-
To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Medications as categorial variables
-
To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients
Time frame: Between the first january 2004 and the 31th december 2021
Type of first symptoms as categorial variables
-
To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients
Time frame: Between the first january 2004 and the 31th december 2021
Date of first symptoms as quantitative variable
-
To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
pO2 (in mmHg)
-
To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
PCR (mg/L)
-
To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
WBC (G/L)
-
To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Creatinine (µmol/L)
-
To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
LDH (MUI/L)
-
To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
albumin (g/L)
-
To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
immunoglobulin (g/L)
-
To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
lymphocytes (G/L)
-
To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
PCR pneumocystis in ct
-
To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Immunofluorescence as a categorial variable
-
To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Specific coloration as a categorial variable
-
To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Nasal canula as a categorial variable
-
To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
High flow oxygenation as a categorial variable
-
To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Mechanical ventilation as a categorial variable
-
To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
Duration in days
-
To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
cotrimoxazole as a categorial variable
-
To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
atovaquone as a categorial variable
-
To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
pentamidine as a categorial variable
-
To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia
Time frame: Between the first january 2004 and the 31th december 2021
steroïd as a categorial variable
Sponsors and collaborators
Lead sponsor
Central Hospital, Nancy, France
Other
Registry information
Official study title
Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients : a Prognostic Observational Retrospective Monocentre Study
Acronym: PnP-HIV-Free
Important dates
- Study start
- 2020
- Primary completion
- 2023
- Study completion
- 2023
- First posted
- Jul 14, 2022
- Registry last updated
- Jul 5, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
NCT05707156
Aspergillosis, Bacterial Infections and Mycoses
Denver, Colorado, United States
View Trial Details
Recruiting
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
NCT04851015
Bacterial Infections and Mycoses, Infections
Montreal, Quebec, Canada
View Trial Details
Not Yet Recruiting
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
NCT07357103
Bacterial Infections and Mycoses, Infections
View Trial Details
Not Yet Recruiting
How Long Should we Give Steroids for Patients With Severe PCP
NCT07328984
Bacterial Infections and Mycoses, Infections
Montreal, Quebec, Canada
View Trial Details